Vertex Pharmaceuticals operates at the forefront of scientific innovation and has successfully developed and commercialized multiple breakthrough medicines for Cystic Fibrosis (CF), Casgevy, a gene therapy for sickle cell disease and beta-thalassemia and Journavx, a novel new treatment for moderate to severe acute pain. Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases including programs in kidney diseases, Type 1 diabetes, among others.
Povetacicept is a highly potent and effective dual antagonist of BAFF and APRIL pathways with potential best-in-class efficacy in patients with IgA nephropathy (IgAN). IgAN is a serious, progressive, autoimmune disease of the kidney that can lead to end-stage-renal disease. IgAN is the most common cause of primary (idiopathic) glomerulonephritis worldwide. Due to its mechanism of action as a dual BAFF/APRIL antagonist, povetacicept holds the potential to benefit patients for multiple additional serious diseases including other autoimmune kidney diseases and autoimmune cytopenias such as primary membranous nephropathy (pMN) and generalized myasthenia gravis (gMG).
Vertex is seeking a Senior Director of Global Value & Access Strategy (GVAS) for povetacicept, reporting to the ED Kidney Lead, to join our dynamic team in Boston, MA. The Senior Director will be the Market Access Asset Lead for povetacicept in IgA nephropathy (IgAN) and future indications, including pMN and gMG. In this capacity, the individual will be responsible for evolving the global price and access strategy (P&MA) for IgAN and driving development of the LCM/portfolio P&MA strategy, as well as leading the cross-functional, cross-regional Value & Access Strategy Working Team. The successful candidate will serve as the voice of the payer internally to ensure that P&MA implications are considered in key program decisions. This role will also be accountable for leadership of cross-portfolio capability building and thought leadership projects that advance knowledge of and readiness for the rapidly evolving global payer environment.
The successful candidate will be strategic, demonstrate strong cross-functional leadership, thrive in complexity, and have a problem-solving mindset backed by strong analytical skills. The candidate must share our passion for science-based brands that can dramatically improve patients' lives. As a senior member on the GVAS team, the successful candidate must be able to role model Vertex’s ethics & culture and be committed to developing the next generation of leaders. They will also manage two direct reports.
Pay Range:
$240,000 - $360,000
Disclosure Statement:
The range provided is based on what we believe is a reasonable estimate for the base salary pay range for this job at the time of posting. This role is eligible for an annual bonus and annual equity awards. Some roles may also be eligible for overtime pay, in accordance with federal and state requirements. Actual base salary pay will be based on a number of factors, including skills, competencies, experience, and other job-related factors permitted by law.
At Vertex, our Total Rewards offerings also include inclusive market-leading benefits to meet our employees wherever they are in their career, financial, family and wellbeing journey while providing flexibility and resources to support their growth and aspirations. From medical, dental and vision benefits to generous paid time off (including a week-long company shutdown in the Summer and the Winter), educational assistance programs including student loan repayment, a generous commuting subsidy, matching charitable donations, 401(k) and so much more.
Flex Designation:
Hybrid-Eligible Or On-Site Eligible
Flex Eligibility Status:
In this Hybrid-Eligible role, you can choose to be designated as:
1. Hybrid : work remotely up to two days per week; or select
2. On-Site : work five days per week on-site with ad hoc flexibility.
Note: The Flex status for this position is subject to Vertex’s Policy on Flex @ Vertex Program and may be changed at any time.
#LI-Hybrid
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and has made significant advancements in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain — and continues to progress clinical and research programs in these diseases. We also have a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where we have deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Our global headquarters is in Boston, and we have research and development (R&D) sites and commercial offices worldwide. Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. We have also earned a spot on TIME Most Influential Companies, TIME Best Inventions, and Fast Company Most Innovative Companies lists. Our research and medicines have received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the Prix Galien, the Scrip Award and the Breakthrough Prize awards. Read our community guidelines: https://www.vrtx.com/vertexs-community-guidelines/
View company profile →